Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Resources, news and special offers to support you and your professional development during this difficult time.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Convergence 2020 has come and gone, but you can still access recorded sessions, which are available to attendees until 31 December 2020.
Replay the moments of Euro Convergence 2020. Recorded sessions are available to attendees until 31 January 2020.
RAPS' “how to” guide to developing a comprehensive global regulatory strategy for all types of medical devices. Updated September 2020.
From self-assessments to help you identify your strengths and areas to focus on to reference books and online courses that will help you fill in the gaps in your regulatory knowledge, RAPS has the resources to help you prepare for the RAC exam.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
The RAPS website recently experienced issues that we continue to monitor. Certain areas of the site including news may be limited. We apologize for any inconvenience.
Posted 15 October 2014 | By Alexander Gaffney, RAC,
The European Union seems to be making substantial strides in something the US thus far has been unable to do: reducing the use of antibiotics in food-producing animals.
In a new report issued on 15 October 2014, the European Medicines Agency (EMA)—the EU's version of the US Food and Drug Administration (FDA)—announced that between 2010 and 2012, the sales of antibiotics for use in animals fell 15% on average across 20 European countries.
While some of those countries did better than others—some decreases were as small as 0.4%, others as large as 49%--all but two of the countries saw an overall decrease in the number prescribed.
EMA officials called the figures a "positive trend" and "highly welcome" while at the same time cautioning that the report showed plenty of room for "further decrease."
What caused the decline? EMA officials weren't sure, but member states speculated that national programs to increase responsible prescribing, restrictions on the use of medically important antimicrobials, increased awareness of antimicrobial resistance, reduction targets, and "fluctuations in the size and types of animal populations" had all had an effect on the decline.
But while the EU had positive data to report, it contrasts heavily with a similar report showing a similar effect in the US—in the opposite direction.
In a report released by the US Food and Drug Administration (FDA) in late September 2014, the regulator said that the quantity of antimicrobial active ingredients either sold or distributed in food-producing animals had increased by 16% between 2009 and 2012 in the US.
The report also notes there was a 16% increase in the use of medically important antimicrobials. The good news, FDA said, was that there was a slight increase (28% to 32%) in the percentage of medically important drugs being labeled solely for therapeutic indications—a change that makes it harder for the drugs to be used for growth-promoting purposes in the future.
The report is likely to put pressure on FDA to strengthen its current response to the antibiotic overprescribing crisis, which is now based on a voluntary framework.
EMA Report on Antimicrobial Use in the EU
FDA Report on Antimicrobial use in the US
Tags: Antimicrobials, Antibiotics, Antibiotic, Antibiotic Prescribing
Regulatory Focus newsletters
All the biggest regulatory news and happenings.